Clinical Genome Sequencing

Genomic and Personalized Medicine

Volumn 1, Issue , 2013, Pages 102-122

  Green, Robert C ^a   Rehm, Heidi L ^a   Kohane, Isaac S ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Harvard Medical School Center for Biomedical Informatics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84878361900     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-382227-7.00009-4     Document Type: Chapter

References (174)

1. ACOG Committee on Ethics ACOG committee opinion No. 360: Sex selection. Obstet Gynecol 2007, 109:475-478.
2. ACOG Committee on Genetics ACOG committee opinion No. 442: Preconception and prenatal carrier screening for genetic diseases in individuals of Eastern European Jewish descent. Obstet Gynecol 2009, 114:950-953.
3. Adzhubei I., Schmidt S., Peshkin L., et al. A method and server for predicting damaging missense mutations. Nat Methods 2010, 7:248-249.
4. Albert T.J., Molla M.N., Muzny D.M., et al. Direct selection of human genomic loci by microarray hybridization. Nat Methods 2007, 4:903-905.
5. American College of Medical Genetics ACMG Laboratory Standards and Guidelines [online] 2008, American College of Medical Genetics, Bethesda, .
6. Aronson S.J., Clark E.H., Babb L.J., et al. The GeneInsight Suite: A platform to support laboratory and provider use of DNA-based genetic testing. Hum Mutat 2011, 32:532-536.
7. Aronson S.J., Clark E.H., Varugheese M., Baxter S., Babb L.J., Rehm H.L. Communicating new knowledge on previously reported genetic variants. Genet Med 2012, [Epub ahead of print 2012 Apr 5]. 10.1038/gim.2012.19.
8. Ashida S., Koehly L.M., Roberts J.S., Hiraki S., Green R.C. Disclosing the disclosure: Factors associated with communicating the results of genetic susceptibility testing for Alzheimer's disease. J Health Commun 2009, 14:768-784.
9. Ashida S., Koehly L.M., Roberts J.S., Chen C.A., Hiraki S., Green R.C. The role of disease perceptions and results sharing in psychological adaptation after genetic susceptibility testing: The REVEAL Study. Eur J Hum Genet 2010, 18:1296-1301.
10. Ashley E., Butte A., Wheeler M., et al. Clinical assessment incorporating a personal genome. Lancet 2010, 375:1525-1535.
11. Azam S.M., Jozic J. Variable platelet responsiveness to aspirin and clopidogrel: Role of platelet function and genetic polymorphism testing. Transl Res 2009, 154:309-313.
12. Bainbridge M.N., Wiszniewski W., Murdock D.R., et al. Whole-genome sequencing for optimized patient management. Sci Transl Med 2011, 3:87re3.
13. Bell C., Dinwiddie D., Miller N., et al. Carrier testing for severe childhood recessive diseases by next-generation sequencing. Sci Transl Med 2011, 3:65ra4.
14. Bentley D., Balasubramanian S., Swerdlow H., et al. Accurate whole human genome sequencing using reversible terminator chemistry. Nature 2008, 456:53-59.
15. Berg J.S., Khoury M.J., Evans J.P. Deploying whole genome sequencing in clinical practice and public health: Meeting the challenge one bin at a time. Genet Med 2011, 13:499-504.
16. Beutler E., Felitti V., Koziol J., Ho N., Gelbart T. Penetrance of 845G→A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002, 359:211-218.
17. Bloss C., Schork N., Topol E. Effect of direct-to-consumer genomewide profiling to assess disease risk. N Engl J Med 2011, 364:524-534.
18. Bonello L., Palot-Bonello N., Armero S., Camoin-Jau L., Paganelli F. Impact of loading dose adjustment on platelet reactivity in homozygotes of the 2C19 2* loss of function *polymorphism. Int J Cardiol 2010, 145:165-166.
19. Brauer C., Bozic K. Using observational data for decision analysis and economic analysis. J Bone Joint Surg Am 2009, 91A:73-79.
20. Buchdunger E., Cioffi C.L., Law N., et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000, 295:139-145.
21. Caraco Y., Sheller J., Wood A.J. Pharmacogenetic determination of the effects of codeine and prediction of drug interactions. J Pharmacol Exp Ther 1996, 278:1165-1174.
22. Cassa C., Schmidt B., Kohane I., Mandl K. My sister's keeper? Genomic research and the identifiability of siblings. BMC Med Genomics 2008, 1:32.
23. Cassa C.A., Savage S.K., Taylor P.L., Green R.C., McGuire A.L., Mandl K.D. Disclosing pathogenic variants to research participants: Quantifying an emerging ethical responsibility. Genome Res 2012, 22(3):421-428.
24. Castaigne S., Chomienne C., Daniel M.T., et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 1990, 76:1704-1709.
25. Chao S., Roberts J.S., Marteau T.M., Silliman R., Cupples L.A., Green R.C. Health behavior changes after genetic risk assessment for Alzheimer disease: The REVEAL study. Alzheimer Dis. Assoc. Disord. 2008, 22(1):94-97.
26. Chiu R.W., Akolekar R., Zheng Y.W., et al. Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: Large scale validity study. BMJ 2011, 342:c7401.
27. Cho A., Killeya-Jones L., O'Daniel J., et al. Effect of genetic testing for risk of type 2 diabetes mellitus on health behaviors and outcomes: Study rationale, development, and design. BMC Health Serv. Res. 2012, 12(16). [Epub 2012 Jan 18].
28. Choi M., Scholl U., Ji W., et al. Genetic diagnosis by whole exome capture and massive parallel DNA sequencing. Proc Natl Acad Sci USA 2009, 106:19,096-19,101.
29. Christensen K., Roberts J., Uhlmann W., Green R.C. Changes to perceptions of the pros and cons of genetic susceptibility testing after APOE genotyping for Alzheimer disease risk. Genet Med 2011, 13:409-414.
30. Church D.M., Schneider V.A., Graves T., et al. Modernizing reference genome assemblies. PLoS Biol 2011, 9:e1001091.
31. Clayton E.W., McGuire A.L. The legal risks of returning results of genomics research. Genet Med 2012, 14. [Epub.]. 10.1038/gim.2012.10.
32. Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. 2011. Pharmacogenomics knowledge base [online]. <>. http://www.pharmgkb.org/index.jsp.
33. Costa T., Scriver C.R., Childs B. The effect of Mendelian disease on human health: A measurement. Am J Med Genet 1985, 21:231-242.
34. Cotton R.G. Collection of variation causing disease - the human variome project. Hum Genomics 2009, 3:301-303.
35. Daly A.K., Donaldson P.T., Bhatnagar P., et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009, 41:816-819.
36. Dave S.S., Fu K., Wright G.W., et al. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 2006, 354:2431-2442.
37. Demetri G.D., Von Mehren M., Blanke C.D., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002, 347:472-480.
38. Devaney S.A., Palomaki G.E., Scott J.A., Bianchi D.W. Noninvasive fetal sex determination using cell-free fetal DNA: A systematic review and meta-analysis. JAMA 2011, 306:627-636.
39. Downing G.J. Key aspects of health system change on the path to personalized medicine. Transl Res 2009, 154:272-276.
40. Eckert S.L., Katzen H., Roberts J.S., et al. Recall of disclosed Apolipoprotein E genotype and lifetime risk estimate for Alzheimer's disease: The REVEAL study. Genet Med 2006, 8:746-751.
41. Erez A., Plunkett K., Sutton V.R., McGuire A.L. The right to ignore genetic status of late onset genetic disease in the genomic era: Prenatal testing for Huntington disease as a paradigm. Am J Med Genet 2010, 152A:1774-1780.
42. Evans J., Meslin E., Marteau T., Caulfield T. Genomics. Deflating the genomic bubble. Science 2011, 331:861-862.
43. Evans J.P., Green R.C. Direct to consumer genetic testing: Avoiding a culture war. Genet Med 2009, 11:1-2.
44. Fabsitz R., McGuire A., Sharp R., et al. Ethical and practical guidelines for reporting genetic research results to study participants: Updated guidelines from a National Heart, Lung, and Blood Institute working group. Circ Cardiovasc Genet 2010, 3:574-580.
45. Farrer L.A., Cupples L.A., Haines J.L., et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer disease meta analysis consortium. JAMA 1997, 278:1349-1356.
46. Feero W., Guttmacher A., Collins F. Genomic medicine: An updated primer. N Engl J Med 2010, 362:2001-2011.
47. Fitzgerald R., Pirmohamed M. Aspirin resistance: Effect of clinical, biochemical and genetic factors. Pharmacol Ther 2011, 130:213-225.
48. Flaherty K.T., Puzanov I., Kim K.B., et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010, 363:809-819.
49. Fokkema I.F., Taschner P.E., Schaafsma G.C., Celli J., Laros J.F., Den Dunnen J.T. LOVD v.2.0: The next generation in gene variant databases. Hum Mutat 2011, 32:557-563.
50. Frueh F.W., Greely H.T., Green R.C., Hogarth S., Siegel S. The future of direct-to-consumer clinical genetic tests. Nat Rev Genet 2011, 12:511-515.
51. GeneTests GeneTests: Medical Genetics Information Resource [online] 2011, University of Washington, Seattle, WA, .
52. Gilissen C., Hoischen A., Brunner H.G., Veltman J.A. Unlocking Mendelian disease using exome sequencing. Genome Biol 2011, 12:228.
53. Gladding P., White H., Voss J., et al. Pharmacogenetic testing for clopidogrel using the rapid INFINITI analyzer: A dose-escalation study. JACC Cardiovasc Interv 2009, 2:1095-1101.
54. Gnirke A., Melnikov A., Maguire J., et al. Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat Biotechnol 2009, 27:182-189.
55. Goldenberg A.J., Sharp R.R. The ethical hazards and programmatic challenges of genomic newborn screening. JAMA 2012, 307:461-462.
56. Goldsmith L., Jackson L., O'Connor A., Skirton H. Direct-to-consumer genomic testing: Systematic review of the literature on user perspectives. Eur J Hum Genet 2012, [Epub.]. 10.1038/ejhg.2012.18.
57. Gollust S.E., Gordon E.S., Zayac C., et al. Motivations and perceptions of early adopters of personalized genomics: Perspectives from research participants. Publ Health Genomics 2012, 15:22-30.
58. Gonzaga-Jauregui C., Lupski J.R., Gibbs R. Human genome sequencing in health and disease. Ann Rev Med 2012, 63:35-61.
59. Grant R.W., Meigs J.B., Florez J.C., et al. Design of a randomized trial of diabetes genetic risk testing to motivate behavior change: The genetic counseling/lifestyle change (GC/LC) study for diabetes Prevention. Clin Trials 2011, 8:609-615.
60. Grant R.W., O'Brien K.E., Waxler J.L., et al. Personalized genetic risk counseling to motivate diabetes prevention. Diabetes Care 2012, In Press.
61. Green R.C., Roberts J.S., Cupples L.A., et al. Disclosure of APOE genotype for risk of Alzheimer's disease. N Engl J Med 2009, 361:245-254.
62. Green R.C., Berg J.S., Berry G.T., et al. Exploring concordance and disordance for return of incidental findings from clinical sequencing. Genet Med. 2012, 14(4):405-410. Epub 2012 Mar 15. 10.1038/gim.2012.21.
63. Guttmacher A., McGuire A., Ponder B., Stefansson K. Personalized genomic information: Preparing for the future of genetic medicine. Nat Rev Genet 2010, 11:161-165.
64. Guttmacher A.E., Collins F.S. Welcome to the genomic era. N Engl J Med 2003, 349:996-998.
65. Hiraki S., Chen C., Roberts J., Cupples L., Green R.C. Perceptions of familial risk in those seeking a genetic risk assessment for Alzheimer's disease. J Genet Couns 2009, 18:130-136.
66. Hoischen A., Van Bon B., Gilissen C., et al. De novo mutations of SETBP1 cause Schinzel-Giedion syndrome. Nat Genet 2010, 42:483-485.
67. Holmes M.V., Shah T., Vickery C., Smeeth L., Hingorani A.D., Casas J.P. Fulfilling the promise of personalized medicine? Systematic review and field synopsis of pharmacogenetic studies. PLoS One 2009, 4:e7960.
68. Huang M.E., Ye Y.C., Chen S.R., et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988, 72:567-572.
69. Hull S.C., Sharp R.R., Botkin J.R., et al. Patients' views on identifiability of samples and informed consent for genetic research. Am J Bioeth 2008, 8:62-70.
70. James K., Cowl C., Tilburt J., et al. Impact of direct-to-consumer predictive genomic testing on risk perception and worry among patients receiving routine care in a preventive health clinic. Mayo Clin Proc 2011, 86(10):933-940.
71. Janssens A., Van Duijn C. Genome-based prediction of common diseases: Methodological considerations for future research. Genome Med 2009, 1:20.
72. Jonas D.E., McLeod H.L. Genetic and clinical factors relating to warfarin dosing. Trends Pharmacol Sci 2009, 30:375-386.
73. Joneja A., Huang X. A device for automated hydrodynamic shearing of genomic DNA. Biotechniques 2009, 46:553-556.
74. Jordan D.M., Kiezum A., Baxter S.M., et al. Development and validation of a computational method for assessment of missense variants in hypertrophic cardiomyopathy. Am J Hum Genet 2011, 88:183-192.
75. Kaufman D.J., Bollinger J.M., Dvoskin R.L., Scott J.A Risky business: Risk perception and the use of medical services among customers of DTC personal genetic testing. J Genet Couns 2012, 21(3):413-422.
76. Khor B., Gardet A., Xavier R.J. Genetics and pathogenesis of inflammatory bowel disease. Nature 2011, 474:307-317.
77. Khoury M., Berg A., Coates R., Evans J., Teutsch S., Bradley L. The evidence dilemma in genomic medicine. Health Aff 2008, 27:1600-1611.
78. Kobelka C.E. Sequencing: The next generation. Moving beyond population-based recessive disease carrier screening. Clin Genet 2011, 80:25-30.
79. Kohane I., Masys D., Altman R. The incidentalome: A threat to genomic medicine. JAMA 2006, 296:212-215.
80. Kohane I., Mandl K., Taylor P., Holm I., Nigrin D., Kunkel L. Medicine. Reestablishing the researcher-patient compact. Science 2007, 316:836-837.
81. Kohane I.S., Hsing M., Kong S.W. Taxonomizing, sizing, and overcoming the incidentalome. Genet Med 2012, 14(4):399-404.
82. Kopits I., Chen C., Roberts J., Uhlmann W., Green R. Willingness to pay for genetic testing for Alzheimer's disease: A measure of personal utility. Genet Test Mol Biomark 2011, 15:871-875.
83. Kraft P., Hunter D.J. Genetic risk prediction - are we there yet?. N Engl J Med 2009, 360:1701-1703.
84. Kumar P., Radhakrishnan J., Chowdhary M.A., Giampietro P.F. Prevalence and patterns of presentation of genetic disorders in a pediatric emergency department. Mayo Clin Proc 2001, 76:777-783.
85. Kumar P., Henikoff S., Ng P.C. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 2009, 4:1073-1081.
86. Kwak E.L., Bang Y.J., Camidge D.R., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-1703.
87. Lam H.Y., Clark M.J., Chen R., et al. Performance comparison of whole-genome sequencing platforms. Nat Biotechnol 2012, 30:78-82.
88. Lander E.S., Linton L.M., Birren B., et al. Initial sequencing and analysis of the human genome. Nature 2001, 409:860-921.
89. LaRusse S., Roberts J., Marteau T., et al. Genetic susceptibility testing versus family history-based risk assessment: Impact on perceived risk of Alzheimer disease. Genet Med 2005, 7:48-53.
90. Lenfant C. Shattuck lecture: Clinical research to clinical practice - lost in translation?. N Engl J Med 2003, 349:868-874.
91. Li H., Homer N. A survey of sequence alignment algorithms for next-generation sequencing. Brief Bioinform 2010, 11:473-483.
92. Linnenbringer E., Roberts J., Hiraki S., Cupples L., Green R.C. "I know what you told me, but this is what I think:" perceived risk of Alzheimer disease among individuals who accurately recall their genetics-based risk estimate. Genet Med 2010, 12:219-227.
93. Lo S.S., Mumby P.B., Norton J., et al. Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol 2010, 28:1671-1676.
94. Lo Y., Chan K., Sun H., et al. Maternal plasma DNA sequencing reveals the genome-wide genetic and mutational profile of the fetus. Sci Transl Med 2010, 2. 61ra91.
95. Lupski J., Reid J., Gonzaga-Jauregui C., et al. Whole-genome sequencing in a patient with Charcot-Marie-Tooth Neuropathy. N Engl J Med 2010, 362:1181-1191.
96. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
97. MacConaill L.E., Garraway L.A. Clinical implications of the cancer genome. J Clin Oncol 2010, 28:5219-5228.
98. Malpas P. The right to remain in ignorance about genetic information - can such a right be defended in the name of autonomy?. NZ Med J 2005, 118:U1611.
99. Manolio T.A., Collins F.S., Cox N.J., et al. Finding the missing heritability of complex diseases. Nature Review 2009, 461(7265):747-753.
100. Mardis E.R. The impact of next-generation sequencing technology on genetics. Trends Genet 2008, 24:133-141.
101. Margulies M., Egholm M., Altman W.E., et al. Genome sequencing in microfabricated high-density picolitre reactors. Nature 2005, 437:376-380.
102. McCarthy M.I., Abecasis G.R., Cardon L.R., et al. Genome-wide association studies for complex traits: Consensus, uncertainty and challenges. Nat Rev. Genet. 2008, 9(5):356-369.
103. McCormack M., Alfirevic A., Bourgeois S., et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 2011, 364:1134-1143.
104. McDermott U., Downing J., Stratton M. Genomics and the continuum of cancer care. N Engl J Med 2011, 364:340-350.
105. McGuire A., Diaz C., Wang T., Hilsenbeck S. Social networkers' attitudes toward direct-to-consumer personal genome testing. Am J Bioeth 2009, 9:3-10.
106. McGuire A.L., Burke W. An unwelcome side effect of direct-to-consumer personal genome testing: Raiding the medical commons. JAMA 2008, 300:2669-2671.
107. McKernan K.J., Peckham H.E., Costa G.L., et al. Sequence and structural variation in a human genome uncovered by short-read, massively parallel ligation sequencing using two-base encoding. Genome Res 2009, 19:1527-1541.
108. Mega J.L., Close S.L., Wiviott S.D., et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: A pharmacogenetic analysis. Lancet 2010, 376:1312-1319.
109. Mega J.L., Simon T., Collet J.P., et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: A meta-analysis. JAMA 2010, 304:1821-1830.
110. Meyerson M., Gabriel S., Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet 2010, 11:685-696.
111. Mok T.S., Wu Y.L., Thongprasert S., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
112. Moussa I. Coronary artery bifurcation interventions: The disconnect between randomized clinical trials and patient-centered decision-making. Catheter Cardiovasc Interv 2011, 77:537-545.
113. Murphy J., Scott J., Kaufman D., Geller G., LeRoy L., Hudson K. Public expectations for return of results from large-cohort genetic research. Am J Bioeth 2008, 8:36-43.
114. National Heart, Lung and Blood Institute NHLBI GO Exome Sequencing Project (ESP): The Exome Variant Server 2012, University of Washington, .
115. National Institute of Child Health and National Human Genome Research Institute. 2010. Newborn Screening in the genomic era: Setting a research agenda, 13-14 December, 2010, Rockville, MD. Meeting Summary [online]. Newborn Screening Translational Research Network. <>. http://www.genome.gov/Pages/PolicyEthics/StaffArticles/Newborn_Screening_Meeting_Summary.pdf.
116. Ng P.C., Henikoff S. SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res 2003, 31:3812-3814.
117. Ng S.B., Turner E.H., Robertson P.D., et al. Targeted capture and massively parallel sequencing of twelve human exomes. Nature 2009, 461:272-276.
118. Ng S., Buckingham K., Lee C., et al. Exome sequencing identifies the cause of a Mendelian disorder. Nat Genet 2010, 42:30-35.
119. Ng S.B., Bigham A.W., Buckingham K.J., et al. Exome sequencing identifies MLL2 mutations as a cause of Kabuki syndrome. Nat Genet 2010, 42:790-793.
120. Offit K., Groeger E., Turner S., Wadsworth E., Weiser M. The "duty to warn" a patient's family members about hereditary disease risks. JAMA 2004, 292:1469-1472.
121. O'Connell M.J., Lavery I., Yothers G., et al. Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J. Clin. Oncol. 2010, 28(5):3937-3944.
122. O'Roak B.J., Deriziotis P., Lee C., et al. Exome sequencing in sporadic autism spectrum disorders identifies severe de novo mutations. Nat Genet 2011, 43:585-589.
123. Paez J.G., Janne P.A., Lee J.C., et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
124. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351:2817-2826.
125. Palomaki G.E., Kloza E.M., Lambert-Messerlian G.M., et al. DNA sequencing of maternal plasma to detect Down syndrome: An international clinical validation study. Genet Med 2011, 13:913-920.
126. Palomaki G.E., Deciu C., Kloza E.M., et al. DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: An international collaborative study. Genet Med 2012, 14. [Epub.]. 10.1038/gim.2011.73.
127. Pao W., Wang T.y., Riely G.l., et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2005, 2(1):e17.
128. Patwardhan R.P., Lee C., Litvin O., Young D.L., Pe'er D., Shendure J. High-resolution analysis of DNA regulatory elements by synthetic saturaton mutagenesis. Nat Biotechnol 2009, 27:1173-1175.
129. Petitti D., Teutsch S., Barton M., Sawaya G., Ockene J., DeWitt T. Update on the methods of the U.S. Preventive Services Task Force: Insufficient evidence. Ann Intern Med 2009, 150:199-205.
130. Pirmohamed M. Pharmacogenetics of idiosyncratic adverse drug reactions. Handb Exp Pharmacol 2010, (196):477-491.
131. Pirmohamed M. Pharmacogenetics: Past, present and future. Drug Discov Today 2011, 16(1920):852-861.
132. Pleasance E., Cheetham R., Stephens P., et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 2010, 463:191-196.
133. Porreca G.J., Zhang K., Li J.B., et al. Multiplex amplification of large sets of human exons. Nat Methods 2007, 4:931-936.
134. Prenen H., Guetens G., De Boeck G., et al. Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines. Pharmacology 2006, 77:11-16.
135. President's Council on Bioethics. 2008. The changing moral focus of newborn screening: An ethical analysis by the President's Council on Bioethics - Chapter 3: The future of newborn screening. <>. http://bioethics.georgetown.edu/pcbe/reports/newborn_screening/.
136. Price M.J., Berger P.B., Teirstein P.S., et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: The GRAVITAS randomized trial. JAMA 2011, 305:1097-1105.
137. Ratner M. Genomics through the lens of precompetitive data sharing. IN VIVO 2012, 30:46-50.
138. Relling M., Klein T.E. CPIC: Clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clin Pharmacol Ther 2011, 89:464-467.
139. Relling M., Altman R., Goetz M., Evans W. Clinical implementation of pharmacogenomics: Overcoming genetic exceptionalism. Lancet Oncol 2010, 11:507-509.
140. Relling M.V., Hancock M.L., Rivera G.K., et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 1999, 91:2001-2008.
141. Roberts J.S., LaRusse S.A., Katzen H., et al. Reasons for seeking genetic susceptibility testing among first-degree relatives of people with Alzheimer's Disease. Alzheimer's Dis Assoc Dis 2003, 17:86-93.
142. Roberts J.S., Barber M., Brown T.M., et al. Who seeks genetic susceptibility testing for Alzheimer's disease? Findings from a multisite, randomized clinical trial. Genet Med 2004, 6:197-203.
143. Rosenwald A., Wright G., Chan W.C., et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:1937-1947.
144. Rubenstein W., Jiang H., Dellafave L., Rademaker A. Cost-effectiveness of population based BRCA 1/2 testing and ovarian cancer prevention for the Ashkenazi Jews: A call for dialogue. Genet Med 2009, 11:629-639.
145. Samuels M.E., Rouleau G.A. The case for locus-specific databases. Nat Rev Genet 2011, 12:378-379.
146. Schaeffeler E., Fischer C., Brockmeier D., et al. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics 2004, 14:407-417.
147. Shalowitz D.I., Miller F.G. Disclosing individual results of clinical research: Implications of respect for participants. JAMA 2005, 294:737-740.
148. Sharp R. Downsizing genomic medicine: Approaching the ethical complexity of whole-genome sequencing. Genet Med 2011, 13:191-194.
149. Stenson P., Mort M., Ball E., et al. The human gene mutation database: 2008 update. Genome Med 2009, 1:13.
150. Stratton M., Campbell P., Futreal P. The cancer genome. Nature 2009, 458:719-724.
151. Takala T. The right to genetic ignorance confirmed. Bioethics 1999, 13:288-293.
152. Taylor D.H., Cook-Deegan R.M., Hiraki S., Roberts J.S., Blazer D.G., Green R.C. Genetic testing for Alzheimer's and long-term care insurance. Health Aff (Millwood) 2010, 29:102-108.
153. Taylor P. Personal genomes: When consent gets in the way. Nature 2008, 456:32-33.
154. Tewhey R., Warner J.B., Nakano M., et al. Microdroplet-based PCR enrichment for large-scale targeted sequencing. Nat Biotechnol 2009, 27:1025-1031.
155. Tong M.Y., Cassa C.A., Kohane I.S. Automated validation of genetic variants from large databases: Ensuring that variant references refer to the same genomic locations. Bioinformatics 2011, 27:891-893.
156. Travis S. New thinking: Theory vs practice. A case study illustrating evidence-based therapeutic decision making. Colorectal Dis 2006, 8(Suppl. 1):25-29.
157. Van't Veer L.J., Dai H., Van de Vijver M.J., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536.
158. Varmus H. Ten years on: The human genome and medicine. N Engl J Med 2010, 362:2028-2029.
159. Venter J.C., Adams M.D., Myers E.W., et al. The sequence of the human genome. Science 2001, 291:1304-1351.
160. Vernarelli J.A., Roberts J.S., Hiraki S., Chen C.A, Cupples L.A., Green R.C. Effect of Alzheimer's disease genetic risk disclosure on dietary supplement use. Am J Clin Nutr 2010, 91:1402-1407.
161. Visscher P.M., Brown M.A., McCarthy M.I., Yang J. Five years of GWAS discovery. Am. J. Hum. Genet. 2012, 90(1):7-24.
162. Vogel C.L., Cobleigh M.A., Tripathy D., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002, 20:719-726.
163. Waisbren S.E., Albers S., Amato S., et al. Effect of expanded newborn screening for biochemical genetic disorders on child outcomes and parental stress. JAMA 2003, 290:2564-2572.
164. Wang Y., Klijn J.G., Zhang Y., et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005, 365:671-679.
165. Weiss S.T., McLeod H.L., Flockhart D.A., et al. Creating and evaluating genetic tests predictive of drug response. Nat Rev 2008, 7:568-574.
166. Wilson J. To know or not to know? Genetic ignorance, autonomy and paternalism. Bioethics 2005, 19:492-504.
167. Wilson J., Jungner F. Principles and practice of screening for disease. Public Health Papers 1968, World Health Organization, Geneva.
168. Wolf S.M., Lawrenz F.P., Nelson C.A., et al. Managing incidental findings in human subjects research: Analysis and recommendations. J Law Med Ethics 2008, 36(219-248):211.
169. Wolf S.M., Crock B.N., Van Ness B., et al. Managing incidental findings and research results in genomic research involving biobanks and archived datasets. Genet Med 2012, 14(4):361-384.
170. Wood H.M., Belvedere O., Conway C., et al. Using next-generation sequencing for high resolution multiplex analysis of copy number variation from nanogram quantities of DNA from formalin-fixed paraffin-embedded specimens. Nucleic Acids Res 2010, 38:e151.
171. Worthey E.A., Mayer A.N., Syverson G.D., et al. Making a definitive diagnosis: Successful clinical application of whole exome sequencing in a child with intractable inflammatory bowel disease. Genet Med 2011, 13:255-262.
172. Yates C.R., Krynetski E.Y., Loennechen T., et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: Genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997, 126:608-614.
173. Yin T., Miyata T. Pharmacogenomics of clopidogrel: Evidence and perspectives. Thromb Res 2011, 128:307-316.
174. Zick C.D., Mathews C.J., Roberts J., Cook-Deegan R., Pokorski R.J., Green R.C. Genetic testing for Alzheimer's disease and its impact on insurance purchasing behavior. Health Aff 2005, 24:483-490.